Why End­points is bring­ing a new fo­cus to our man­u­fac­tur­ing cov­er­age

I’m ex­cit­ed to share that to­day we’re de­but­ing a re­fresh of our man­u­fac­tur­ing cov­er­age here at End­points News.

The Covid-19 pan­dem­ic re­shaped the role and promi­nence of man­u­fac­tur­ing in the bio­phar­ma­ceu­ti­cal world, thrust­ing the in­dus­try in­to the spot­light for pub­lic and pri­vate in­vestors, reg­u­la­tors and the pub­lic. And with the ex­plo­sion of cell and gene ther­a­pies, the role of man­u­fac­tur­ing — both in­side com­pa­nies and at con­trac­tors — has be­come even more cru­cial to the suc­cess of some of the fu­ture of biotech. With that has come in­creased fo­cus from reg­u­la­tors, who are giv­ing high lev­els of scruti­ny to in­no­v­a­tive but hard-to-make new ther­a­pies.

Start­ing to­day, An­na Brown in Lon­don will be tak­ing over our man­u­fac­tur­ing re­port that shows up in your in­box each Thurs­day. (If you don’t get it, you can sign up for it here.) An­na will be aid­ed by our new Lon­don ed­i­tor, Rey­nald Cas­tañe­da, with con­tri­bu­tions from Lia De­G­root in Wash­ing­ton, as well as the se­nior ed­i­tor for our phar­ma re­port, Zach Bren­nan.

This week, we’re bring­ing you an ex­clu­sive in­ter­view with a top ex­ec­u­tive at Lon­za, cov­er­age of the US’ ef­forts to ease a short­age of cru­cial can­cer drugs, news of a ma­jor new fa­cil­i­ty in Eu­rope and more scoops, smart analy­sis and break­ing news. As An­na set­tles in, you can ex­pect more ac­cess to con­ver­sa­tions with the most im­por­tant peo­ple in the in­dus­try as well as com­pre­hen­sive cov­er­age you need to keep track of what’s hap­pen­ing.

We’re al­ways look­ing for sto­ry ideas, great peo­ple to in­ter­view and your feed­back, so feel free to reach out to An­na by email.

Thanks for read­ing!